Cite

HARVARD Citation

    Franken, M. et al. (2017). Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. European journal of cancer. pp. 204-212. [Online]. 
  
Back to record